Selected data models

You must log in to select data models for download or further analysis.

6 Search results.
Relevance Rating New first Old first

Screening Genzyme Chronic Kidney Disease EudraCT 2005-003233-41

- 9/16/16 - 1 form, 13 itemgroups, 99 items, 1 language
Itemgroups: Patient administration, Inclusion Criteria, Exclusion criteria, Patient demographics, Vital signs, Weight and Height, Medical/Surgical History, Renal history, 2. Type of Current Phosphate Binders:, Physical Exam, Laboratory Evaluations, Concomitant Medication, Washout/Drug Dispensing
An open label, dose titration study of sevelamer carbonate tablets dosed three times a day in hyperphosphatemic chronic kidney disease patients not on dialysis Name of Sponsor: Genzyme Europe BV Country: Netherlands https://www.clinicaltrialsregister.eu/ctr-search/trial/2005-003233-41/DE#A

Pre-Screening Log RICH study NCT02669589

- 7/8/16 - 1 form, 3 itemgroups, 9 items, 1 language
Itemgroups: Patient Information, Inclusion Criteria, Reason for Exclusion
NCT02669589 EudraCT-Nr. 2014-004854-33 REGIONAL CITRATE VERSUS SYSTEMIC HEPARIN ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN CRITICALLY ILL PATIENTS WITH ACUTE KIDNEY INJURY Study Chair: Alexander Zarbock, MD University Hospital Muenster

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Screening

- 8/16/19 - 1 form, 12 itemgroups, 75 items, 1 language
Itemgroups: Administrative documentation, Demography, Vital signs, Rectal Carcinoma, Medical History, Rectal Carcinoma, Operative Surgical Procedures, Previous, 12 lead ECG, Rectal Carcinoma, Evaluation, Diagnostic procedure, Disease, Relationships, Rectal Carcinoma, Medical History; History of surgical procedures; Physical Examination, Pharmaceutical Preparations, Previous; Concomitant Agent, Inclusion, Exclusion Criteria
Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - Laboratory Tests (Annex Report 2 Final)

- 10/28/20 - 1 form, 8 itemgroups, 16 items, 1 language
Itemgroups: Administrative, Laboratory Tests, Laboratory Assay, Haematology, Biochemistry, Hepatic Function, Renal Function, HCG Urine or Blood Pregnancy Test
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Screening - Laboratory Tests

- 8/25/20 - 1 form, 8 itemgroups, 16 items, 1 language
Itemgroups: Administrative, Laboratory Tests, Laboratory Assay, Haematology, Biochemistry, Hepatic Function, Renal Function, HCG Urine or Blood Pregnancy Test
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Screening

- 12/15/19 - 1 form, 23 itemgroups, 125 items, 1 language
Itemgroups: Administrative documentation, Demography, Vital signs, Disease, Physical Examination, Allen test, Alcohol consumption, Urine drug screening; Ethanol measurement, breath test expired carbon monoxide, Serologic tests, Mini International Neuropsychiatric Interview, Laboratory Procedures, Hematology finding, Laboratory Procedures, Chemistry, Clinical, Urinalysis, Laboratory Procedures, Renal function, Blood, Laboratory Procedures, Renal function, Urine, 12 lead ECG, Holter Electrocardiography, Eligibility Determination, Inclusion, Exclusion Criteria, 12 lead ECG, Abnormality, Holter Electrocardiography, Abnormality
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial